{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:24Z","timestamp":1792979904521,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12975-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:55:13Z","timestamp":1773370513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Determinants and outcomes of adverse drug reactions among people living with HIV on antiretroviral therapy in Nigeria"],"prefix":"10.1186","volume":"26","author":[{"given":"Victoria P.","family":"Etuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikeola A.","family":"Adeoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobolaji M.","family":"Salawu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo I.","family":"Fawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"12975_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","volume":"384","author":"G Maartens","year":"2014","unstructured":"Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384:258\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(14)60164-1.","journal-title":"Lancet"},{"key":"12975_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40264-015-0295-7","volume":"38","author":"WM Bezabhe","year":"2015","unstructured":"Bezabhe WM, Bereznicki LR, Chalmers L. Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study From Ethiopia. Drug Saf. 2015;38:629\u201339. https:\/\/doi.org\/10.1007\/s40264-015-0295-7.","journal-title":"Drug Saf"},{"key":"12975_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0179769","volume":"12","author":"MJ Wolff","year":"2017","unstructured":"Wolff MJ, Giganti MJ, Cortes CP, Cahn P, Grinsztejn B, Pape JW, et al. A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy. PLoS ONE. 2017;12:1\u201315. https:\/\/doi.org\/10.1371\/journal.pone.0179769.","journal-title":"PLoS ONE"},{"key":"12975_CR4","doi-asserted-by":"publisher","unstructured":"Federal Ministry of Health N, National AIDS, STI\u2019s Control, Programme. Federal ministry of health: national guidelines for HIV prevention treatment and care. 2016. https:\/\/doi.org\/10.1016\/j.anbehav.2014.09.030.","DOI":"10.1016\/j.anbehav.2014.09.030"},{"key":"12975_CR5","unstructured":"UNAIDS, Country factsheets NIGERIA. 2017 HIV and AIDS Estimates Adults and children living with Country factsheets NIGERIA. 2017 HIV testing and treatment cascade people living with HIV coverage of adults and children. Unaids. 2019."},{"key":"12975_CR6","unstructured":"NACA. Revised National HIV and AIDS Strategic Framework 2021\u20132025. National Agency for the Control of HIV\/AIDS. 2019. 8:15\u201320."},{"key":"12975_CR7","doi-asserted-by":"publisher","first-page":"P55","DOI":"10.1186\/1471-2334-12-s1-p55","volume":"12","author":"P Pulagam","year":"2012","unstructured":"Pulagam P, Rajesh R, Vidyasagar S, Varma D. Assessment of hematological adverse drug reactions to antiretroviral therapy in HIV positive patients at Kasturba Hospital Manipal. BMC Infect Dis. 2012;12:P55. https:\/\/doi.org\/10.1186\/1471-2334-12-s1-p55.","journal-title":"BMC Infect Dis"},{"key":"12975_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/2229-3485.111784","volume":"4","author":"KA Agu","year":"2013","unstructured":"Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res. 2013;4:117\u201324. https:\/\/doi.org\/10.4103\/2229-3485.111784.","journal-title":"Perspect Clin Res"},{"key":"12975_CR9","doi-asserted-by":"publisher","unstructured":"Shet A, Antony J, Arumugam K, Dodderi SK, Rodrigues R, Decosta A. Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV infected individuals initiating first-line antiretroviral therapy in India. PLoS ONE. 2014;9. https:\/\/doi.org\/10.1371\/journal.pone.0091028.","DOI":"10.1371\/journal.pone.0091028"},{"key":"12975_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-14-1306","volume":"14","author":"DK Tumusiime","year":"2014","unstructured":"Tumusiime DK, Venter F, Musenge E, Stewart A. Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda. BMC Public Health. 2014;14:1\u20138.","journal-title":"BMC Public Health"},{"key":"12975_CR11","doi-asserted-by":"crossref","unstructured":"Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12.","DOI":"10.1186\/1472-6904-12-7"},{"key":"12975_CR12","doi-asserted-by":"publisher","unstructured":"Ogoina D, Obiako RO, Muktar HM, Adeiza M, Babadoko A, Hassan A, et al. Morbidity and mortality patterns of hospitalised adult HIV \/ AIDS patients in the era of highly active antiretroviral therapy: a 4-year retrospective review from Zaria, Northern Nigeria. AIDS Res Treat. 2012;2012. https:\/\/doi.org\/10.1155\/2012\/940580.","DOI":"10.1155\/2012\/940580"},{"key":"12975_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4314\/gmj.v48i4.5","volume":"48","author":"IA Oreagba","year":"2014","unstructured":"Oreagba IA, Usman SO, Olayemi SO, Oshikoya KA, Opanuga O, Lesi OA, et al. PHARMACOEPIDEMIOLOGY OF ANTIRETROVIRAL DRUGS IN A TEACHING HOSPITAL IN LAGOS, NIGERIA. Ghana Med J. 2014;48:194\u2013203.","journal-title":"Ghana Med J"},{"key":"12975_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10461-016-1545-0","volume":"21","author":"H Li","year":"2017","unstructured":"Li H, Marley G, Ma W, Wei C, Lackey M, Ma Q, et al. The Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis. AIDS Behav. 2017;21:341\u201351. https:\/\/doi.org\/10.1007\/s10461-016-1545-0.","journal-title":"AIDS Behav"},{"key":"12975_CR15","doi-asserted-by":"crossref","unstructured":"Prosperi MCF, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012;12.","DOI":"10.1186\/1471-2334-12-296"},{"key":"12975_CR16","doi-asserted-by":"crossref","unstructured":"Tadesse WT, Mekonnen AB, Tesfaye WH, Tadesse YT. Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. BMC Pharmacol Toxicol. 2014;15.","DOI":"10.1186\/2050-6511-15-32"},{"key":"12975_CR17","doi-asserted-by":"publisher","first-page":"A39","DOI":"10.1136\/bmjgh-2016-000260.103","volume":"2","author":"P Bassi","year":"2017","unstructured":"Bassi P, Wadzani G, Klungel O, Alexander D, Prosper O, Phyllis K. Prevalence of adverse drug reactions among hiv\/aids patients on haart in university of maiduguri teaching hospital (umth), nigeria: a four-year retrospective study. BMJ Global Health. 2017;2:A39.","journal-title":"BMJ Global Health"},{"key":"12975_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","volume":"27","author":"Z Shubber","year":"2013","unstructured":"Shubber Z, Calmy A, Andrieux-meyer I, Shaffer N, Vitoria M, Hargreaves S, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403\u201312. https:\/\/doi.org\/10.1097\/QAD.0b013e32835f1db0.","journal-title":"AIDS"},{"key":"12975_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2174\/1389450120666190214144609","volume":"16","author":"IO Abah","year":"2018","unstructured":"Abah IO, Ncube NBQ, Bradley HA, Agbaji OO, Kanki P. Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. Curr HIV Res. 2018;16:436\u201346. https:\/\/doi.org\/10.2174\/1389450120666190214144609.","journal-title":"Curr HIV Res"},{"key":"12975_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-015-0044-0","volume":"12","author":"LJ Masenyetse","year":"2015","unstructured":"Masenyetse LJ, Manda SOM, Mwambi HG. An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Therapy. 2015;12:1\u20138. https:\/\/doi.org\/10.1186\/s12981-015-0044-0.","journal-title":"AIDS Res Therapy"},{"key":"12975_CR21","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/QAD.0000000000001279","volume":"30","author":"MGJ Boer","year":"2016","unstructured":"Boer MGJ, De BGEL, Van Den HN, Van, Oryszcyn JE, Dorama W. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30:2381\u20134. https:\/\/doi.org\/10.1097\/QAD.0000000000001279.","journal-title":"AIDS"},{"key":"12975_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1468-1293.2009.00751.x","volume":"11","author":"N Obel","year":"2010","unstructured":"Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: A population-based nationwide cohort study. HIV Med. 2010;11:130\u20136. https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00751.x.","journal-title":"HIV Med"},{"key":"12975_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink H, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56\u201363. https:\/\/doi.org\/10.1111\/hiv.12468.","journal-title":"HIV Med"},{"key":"12975_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4172\/jaa.1000039","volume":"4","author":"OR Obiako","year":"2012","unstructured":"Obiako OR, Muktar MH, Garko BS, Tobi-Ajayi E, Olayinka AT, Iyanda M, et al. Adverse Reactions Associated with Antiretroviral Regimens in Adult Patients of a University Teaching Hospital HIV Program in Zaria, Northern Nigeria : An Observational Cohort Study Antivirals & Antiretrovirals. J Antivirals Antiretrovirals. 2012;4:6\u201313. https:\/\/doi.org\/10.4172\/jaa.1000039.","journal-title":"J Antivirals Antiretrovirals"},{"key":"12975_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4103\/0976-0105.103824","volume":"3","author":"KA Agu","year":"2012","unstructured":"Agu KA, Oparah AC, Ochei UM. Improving Monitoring and Reporting of Adverse Drug Reactions (ADRs) in HIV positive patients on Antiretroviral Therapy (ART) in Nigeria. J Basic Clin Pharm. 2012;3:299\u2013313.","journal-title":"J Basic Clin Pharm"},{"key":"12975_CR26","unstructured":"Federal Ministry of Health N. Nigeria integrated national guildlines for HIV prevention treatment and care. 2014."},{"key":"12975_CR27","unstructured":"National Agency For Food and Drug Administration And Control (NAFDAC). Handling adverse drug reactions (ADRs). Drug safety. 2024."},{"key":"12975_CR28","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Harmonised tripartite guideline: clinical safety data management: definitions and standards for expedited reporting E2a. Efficacy guidelines. 1994; 12."},{"key":"12975_CR29","unstructured":"WHO. Safety monitoring of medicinal products: reporting systems for the general public. 2000."},{"key":"12975_CR30","volume-title":"Surveillance of antiretroviral toxicity: global HIV, hepatitis and STIs programme: what\u2019s new in person-centred HIV patient and antiretroviral drug toxicity monitoring: technical brief","author":"WH Organization","year":"2020","unstructured":"Organization WH. Surveillance of antiretroviral toxicity: global HIV, hepatitis and STIs programme: what\u2019s new in person-centred HIV patient and antiretroviral drug toxicity monitoring: technical brief. Geneva PP - Geneva: World Health Organization; 2020."},{"key":"12975_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.11599\/germs.2015.1075","volume":"5","author":"IO Abah","year":"2015","unstructured":"Abah IO, Akanbi M, Abah ME, Finangwai AI, Dady CW. Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz. GERMS. 2015;5:83\u201391.","journal-title":"GERMS"},{"key":"12975_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/cid\/cir432","volume":"53","author":"SA Mehta","year":"2011","unstructured":"Mehta SA, Ahmed A, Laverty M, Holzman RS, Valentine F, Sivapalasingam S. Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis. 2011;53:490\u20136. https:\/\/doi.org\/10.1093\/cid\/cir432.","journal-title":"Clin Infect Dis"},{"key":"12975_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20786190.2017.1364013","volume":"60","author":"R Graan","year":"2018","unstructured":"Graan R, Van, Viljoen M, Rheeders M, Motara F, Africa S. Retrospective clinical analysis of adverse drug reactions associated with antiretroviral therapy in Tlokwe district, South Africa. South Afr Family Pract. 2018;60:1\u20136. https:\/\/doi.org\/10.1080\/20786190.2017.1364013.","journal-title":"South Afr Family Pract"},{"key":"12975_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/tmi.13514","volume":"26","author":"OE Awopegba","year":"2021","unstructured":"Awopegba OE, Ologunowa TO, Ajayi AI. HIV testing and self-testing coverage among men and women in South Africa: an exploration of related factors. Tropical Med Int Health. 2021;26:214\u201327. https:\/\/doi.org\/10.1111\/tmi.13514.","journal-title":"Tropical Med Int Health"},{"key":"12975_CR35","unstructured":"NAIIS. National summary sheet preliminary findings findings by sex and and age. 2019."},{"key":"12975_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2165\/00002018-200528120-00003","volume":"28","author":"R Clark","year":"2005","unstructured":"Clark R. Sex Differences in Antiretroviral Therapy-Associated Intolerance and Adverse Events. Drug Saf. 2005;28:1075\u201383.","journal-title":"Drug Saf"},{"key":"12975_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1517\/17425255.2.2.273","volume":"2","author":"OC Umeh","year":"2006","unstructured":"Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metabolism Toxicol. 2006;2:273\u201383. https:\/\/doi.org\/10.1517\/17425255.2.2.273.","journal-title":"Expert Opin Drug Metabolism Toxicol"},{"key":"12975_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/QCO.0000000000000033","volume":"27","author":"JM Greig","year":"2014","unstructured":"Greig JM, Anderson J. Optimizing antiretroviral therapy for women living with HIV. Curr Opin Infect Dis. 2014;27:46\u201352. https:\/\/doi.org\/10.1097\/QCO.0000000000000033.","journal-title":"Curr Opin Infect Dis"},{"key":"12975_CR39","doi-asserted-by":"crossref","unstructured":"Monjok E, Smesny A, Okokon IB, Mgbere O, Essien EJ. Adherence to antiretroviral therapy in Nigeria: an overview of research studies and implications for policy and practice. HIV\/AIDS Research Palliative Care. 2010;2: 69\u201376.","DOI":"10.2147\/HIV.S9280"},{"key":"12975_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/CIA.S37738","volume":"8","author":"LJ Gleason","year":"2013","unstructured":"Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clin Interv Aging. 2013;8:749\u201363. https:\/\/doi.org\/10.2147\/CIA.S37738.","journal-title":"Clin Interv Aging"},{"key":"12975_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0094854","volume":"9","author":"FS Sarfo","year":"2014","unstructured":"Sarfo FS, Sarfo MA, Norman B, Phillips R, Chadwick D. Incidence and Determinants of Nevirapine and Efavirenz- Related Skin Rashes in West Africans: Nevirapine \u2019 s Epitaph ? PLoS ONE. 2014;9:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0094854.","journal-title":"PLoS ONE"},{"key":"12975_CR42","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00228-018-2499-0","volume":"74","author":"S Mugusi","year":"2018","unstructured":"Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, et al. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. Eur J Clin Pharmacol. 2018;74:1405\u201315. https:\/\/doi.org\/10.1007\/s00228-018-2499-0.","journal-title":"Eur J Clin Pharmacol"},{"key":"12975_CR43","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.4314\/ahs.v19i2.19","volume":"19","author":"WP Howlett","year":"2019","unstructured":"Howlett WP. Neurological disorders in HIV in Africa: A review. Afr Health Sci. 2019;19:1953\u201377. https:\/\/doi.org\/10.4314\/ahs.v19i2.19.","journal-title":"Afr Health Sci"},{"key":"12975_CR44","first-page":"115","volume":"12","author":"R Margalida","year":"2007","unstructured":"Margalida R, Sara C, Hansjakob F, Laurent D, Thierry B, Amalio T. Does Tenofovir Influence Efavirenz Pharmacokinetics? Antiviral Res. 2007;12:115\u20138.","journal-title":"Does Tenofovir Influence Efavirenz Pharmacokinetics? Antiviral Res"},{"key":"12975_CR45","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/INF.0b013e31829ec8e5","volume":"32","author":"EJ Dziuban","year":"2013","unstructured":"Dziuban EJ, Hughey AB, Stewart DA, Blank DA, Kochelani D, Draper HR, et al. Stevens \u2013 Johnson Syndrome and HIV in Children in Swaziland. Pediatr Infect Dis J. 2013;32:1354\u20138. https:\/\/doi.org\/10.1097\/INF.0b013e31829ec8e5.","journal-title":"Pediatr Infect Dis J"},{"key":"12975_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.annder.2018.07.022","volume":"145","author":"B Saka","year":"2018","unstructured":"Saka B, Akakpo AS, Bassowa A, Dapam AN, Mahamadou G, Teclessou JN, et al. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. Ann Dermatol Venereol. 2018;145:773\u20136. https:\/\/doi.org\/10.1016\/j.annder.2018.07.022.","journal-title":"Ann Dermatol Venereol"},{"key":"12975_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0060206","volume":"8","author":"T Phe","year":"2013","unstructured":"Phe T, Thai S, Veng C, Sok S, Lynen L, Van J. Risk Factors of Treatment-Limiting Anemia after Substitution of Zidovudine for Stavudine in HIV-Infected Adult Patients on Antiretroviral Treatment. PLoS ONE. 2013;8:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0060206.","journal-title":"PLoS ONE"},{"key":"12975_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3233\/JRS-2011-0532","volume":"23","author":"SR Anwikar","year":"2011","unstructured":"Anwikar SR, Bandekar MS, Smrati B, Pazare AP, Tatke PA, Kshirsagar NA. HAART induced adverse drug reactions: A retrospective analysis at a tertiary referral health care center in India. Int J Risk Saf Med. 2011;23:163\u20139. https:\/\/doi.org\/10.3233\/JRS-2011-0532.","journal-title":"Int J Risk Saf Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12975-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12975-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12975-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:52:40Z","timestamp":1776732760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12975-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12975"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12975-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained ethical approval from the Oyo State Ethics Research Committee [approval number AD\/13\/479\/1768]. In our study, we performed a retrospective analysis of routine pharmacovigilance\/surveillance data, including pediatric data, from the national pharmacovigilance centre database, in accordance with the Declaration of Helsinki. However, the need for informed consent to participate, as well as the need to obtain consent from the parents or legal guardians of minors, was waived by an Institutional Review Board (IRB) because it was deemed unnecessary under national regulations. The data was anonymised and stored on a password-protected device accessible only to the researchers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"791"}}